89 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
candidates, research programs, and technologies; the expected benefits of potential strategic collaborations with third parties, including our agreements … in the field and to develop therapies in which our genome edits confer potential benefits to patients. Further expanding patient access to cell therapies via
8-K
nq8bfmklj5siy
12 Dec 23
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
4:05pm
8-K
EX-1.1
keqbb2l g1
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
424B5
hf3uct lm
14 Jul 23
Prospectus supplement for primary offering
5:31pm
424B5
ovlwral6
13 Jul 23
Prospectus supplement for primary offering
4:56pm
8-K
EX-10.1
6q8il2
6 Jul 23
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
8:01am
ARS
wqpnle
28 Apr 23
Annual report to shareholders
12:00am
8-K
EX-99.1
vwl0m2nh 2ek859mj6vj
29 Nov 22
Regulation FD Disclosure
9:00am